178 related articles for article (PubMed ID: 38755678)
1. CircTRIM1 encodes TRIM1-269aa to promote chemoresistance and metastasis of TNBC via enhancing CaM-dependent MARCKS translocation and PI3K/AKT/mTOR activation.
Li Y; Wang Z; Yang J; Sun Y; He Y; Wang Y; Chen X; Liang Y; Zhang N; Wang X; Zhao W; Hu G; Yang Q
Mol Cancer; 2024 May; 23(1):102. PubMed ID: 38755678
[TBL] [Abstract][Full Text] [Related]
2. Hsa_circ_0000199 facilitates chemo-tolerance of triple-negative breast cancer by interfering with miR-206/613-led PI3K/Akt/mTOR signaling.
Li H; Xu W; Xia Z; Liu W; Pan G; Ding J; Li J; Wang J; Xie X; Jiang D
Aging (Albany NY); 2021 Jan; 13(3):4522-4551. PubMed ID: 33495420
[TBL] [Abstract][Full Text] [Related]
3. Circular RNA UBAP2 facilitates the cisplatin resistance of triple-negative breast cancer via microRNA-300/anti-silencing function 1B histone chaperone/PI3K/AKT/mTOR axis.
Wang L; Yang X; Zhou F; Sun X; Li S
Bioengineered; 2022 Mar; 13(3):7197-7208. PubMed ID: 35263216
[TBL] [Abstract][Full Text] [Related]
4. CircWAC induces chemotherapeutic resistance in triple-negative breast cancer by targeting miR-142, upregulating WWP1 and activating the PI3K/AKT pathway.
Wang L; Zhou Y; Jiang L; Lu L; Dai T; Li A; Chen Y; Zhang L
Mol Cancer; 2021 Mar; 20(1):43. PubMed ID: 33648498
[TBL] [Abstract][Full Text] [Related]
5. TRIM59 predicts poor prognosis and promotes pancreatic cancer progression via the PI3K/AKT/mTOR-glycolysis signaling axis.
Li R; Weng L; Liu B; Zhu L; Zhang X; Tian G; Hu L; Li Q; Jiang S; Shang M
J Cell Biochem; 2020 Feb; 121(2):1986-1997. PubMed ID: 31693252
[TBL] [Abstract][Full Text] [Related]
6. Protective effect of hsa-miR-570-3p targeting CD274 on triple negative breast cancer by blocking PI3K/AKT/mTOR signaling pathway.
Wang LL; Huang WW; Huang J; Huang RF; Li NN; Hong Y; Chen ML; Wu F; Liu J
Kaohsiung J Med Sci; 2020 Aug; 36(8):581-591. PubMed ID: 32311203
[TBL] [Abstract][Full Text] [Related]
7. Micropeptide CIP2A-BP encoded by LINC00665 inhibits triple-negative breast cancer progression.
Guo B; Wu S; Zhu X; Zhang L; Deng J; Li F; Wang Y; Zhang S; Wu R; Lu J; Zhou Y
EMBO J; 2020 Jan; 39(1):e102190. PubMed ID: 31755573
[TBL] [Abstract][Full Text] [Related]
8. GBP2 enhances paclitaxel sensitivity in triple‑negative breast cancer by promoting autophagy in combination with ATG2 and inhibiting the PI3K/AKT/mTOR pathway.
Zhang W; Tang X; Peng Y; Xu Y; Liu L; Liu S
Int J Oncol; 2024 Apr; 64(4):. PubMed ID: 38334171
[TBL] [Abstract][Full Text] [Related]
9. Down-regulating GRP78 reverses pirarubicin resistance of triple negative breast cancer by miR-495-3p mimics and involves the p-AKT/mTOR pathway.
Liu M; Yang J; Lv W; Wang S; Du T; Zhang K; Wu Y; Feng X
Biosci Rep; 2022 Jan; 42(1):. PubMed ID: 34935899
[TBL] [Abstract][Full Text] [Related]
10. FOXD1-AS1 regulates FOXD1 translation and promotes gastric cancer progression and chemoresistance by activating the PI3K/AKT/mTOR pathway.
Wu Q; Ma J; Wei J; Meng W; Wang Y; Shi M
Mol Oncol; 2021 Jan; 15(1):299-316. PubMed ID: 32460412
[TBL] [Abstract][Full Text] [Related]
11. Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review.
Costa RLB; Han HS; Gradishar WJ
Breast Cancer Res Treat; 2018 Jun; 169(3):397-406. PubMed ID: 29417298
[TBL] [Abstract][Full Text] [Related]
12. circPARD3 drives malignant progression and chemoresistance of laryngeal squamous cell carcinoma by inhibiting autophagy through the PRKCI-Akt-mTOR pathway.
Gao W; Guo H; Niu M; Zheng X; Zhang Y; Xue X; Bo Y; Guan X; Li Z; Guo Y; He L; Zhang Y; Li L; Cao J; Wu Y
Mol Cancer; 2020 Nov; 19(1):166. PubMed ID: 33234130
[TBL] [Abstract][Full Text] [Related]
13. Silence of α1-Antitrypsin Inhibits Migration and Proliferation of Triple Negative Breast Cancer Cells.
Zhao Z; Ma J; Mao Y; Dong L; Li S; Zhang Y
Med Sci Monit; 2018 Sep; 24():6851-6860. PubMed ID: 30260937
[TBL] [Abstract][Full Text] [Related]
14. Rhizoma Amorphophalli inhibits TNBC cell proliferation, migration, invasion and metastasis through the PI3K/Akt/mTOR pathway.
Wu C; Qiu S; Liu P; Ge Y; Gao X
J Ethnopharmacol; 2018 Jan; 211():89-100. PubMed ID: 28962890
[TBL] [Abstract][Full Text] [Related]
15. Osteopontin promotes tumor growth and metastasis and GPX4-mediated anti-lipid peroxidation in triple-negative breast cancer by activating the PI3k/Akt/mTOR pathway.
Guo M; Liu M; Li W; Wang C; Zhang L; Zhang H
J Cancer Res Clin Oncol; 2024 Mar; 150(3):155. PubMed ID: 38526702
[TBL] [Abstract][Full Text] [Related]
16. The pan-PI3K inhibitor GDC-0941 activates canonical WNT signaling to confer resistance in TNBC cells: resistance reversal with WNT inhibitor.
Tzeng HE; Yang L; Chen K; Wang Y; Liu YR; Pan SL; Gaur S; Hu S; Yen Y
Oncotarget; 2015 May; 6(13):11061-73. PubMed ID: 25857298
[TBL] [Abstract][Full Text] [Related]
17. Enhanced mitochondrial fission suppresses signaling and metastasis in triple-negative breast cancer.
Humphries BA; Cutter AC; Buschhaus JM; Chen YC; Qyli T; Palagama DSW; Eckley S; Robison TH; Bevoor A; Chiang B; Haley HR; Sahoo S; Spinosa PC; Neale DB; Boppisetti J; Sahoo D; Ghosh P; Lahann J; Ross BD; Yoon E; Luker KE; Luker GD
Breast Cancer Res; 2020 Jun; 22(1):60. PubMed ID: 32503622
[TBL] [Abstract][Full Text] [Related]
18. YY1 mediated DCUN1D5 transcriptional activation promotes triple-negative breast cancer progression by targeting FN1/PI3K/AKT pathway.
Lin Y; Li Y; Chen X; Jin X; Jiang M; Xiao H; Chen L; Chen M; Zhang W; Chen H; Nie Q; Guo R; Guo W; Fu F; Wang C
Biol Direct; 2024 Jun; 19(1):42. PubMed ID: 38831379
[TBL] [Abstract][Full Text] [Related]
19. Doubling down on the PI3K-AKT-mTOR pathway enhances the antitumor efficacy of PARP inhibitor in triple negative breast cancer model beyond BRCA-ness.
De P; Sun Y; Carlson JH; Friedman LS; Leyland-Jones BR; Dey N
Neoplasia; 2014 Jan; 16(1):43-72. PubMed ID: 24563619
[TBL] [Abstract][Full Text] [Related]
20. PRR15 deficiency facilitates malignant progression by mediating PI3K/Akt signaling and predicts clinical prognosis in triple-negative rather than non-triple-negative breast cancer.
Guo F; Ma J; Li C; Liu S; Wu W; Li C; Wang J; Wang J; Li Z; Zhai J; Sun F; Zhou Y; Guo C; Qian H; Xu B
Cell Death Dis; 2023 Apr; 14(4):272. PubMed ID: 37072408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
